FOXP3 and thyroid gland carcinoma: Reports state that long non-coding RNA (lncRNA) fricr is comparable to the Foxp3 genome and has the ability to act cis on Foxp3’s transcription process, decreasing its stability (12); additionally, miR-125b has been shown in thyroid cancer research to target Foxp3 and suppress its mRNA and protein production while increasing cancer cells’ susceptibility to cisplatin treatments (14).